The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Drug-free stents with Polyzene-F nanocoating: a promising compromise for those at high bleeding risk?

EuroIntervention 2019;15:e304-e307. DOI: 10.4244/EIJV15I4A55

1. Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; 2. Deutsches Zentrum für Herz- und Kreislaufforschung e.V., Berlin, Germany; 3. Deutsches Herzzentrum München, Munich, Germany

The clinical benefit of coronary artery stent implantation is largely determined by its ability to suspend reversible ischaemia, while the risk of thrombotic stent occlusion as well as haemorrhagic and vascular complications arising from concomitant pharmacological therapy counterbalance this clinical benefit. The introduction of dual antiplatelet therapy (DAPT) after stenting was a major breakthrough in the history of interventional cardiology1. Coronary stent placement requires a minimum of one month of DAPT (a combination of acetylsalicylic acid [ASA] and a P2Y12 inhibitor) after bare metal stent (BMS) implantation and six months of DAPT after placement of a drug-eluting stent (...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Atrial septal defect and ASO device: an unusual story